Standard BioTools financials
$0.7133−1.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.1M | $21.1M | $23.8M | $19.6M | $21.8M | $20.2M | $24.8M | $22.1M | $22.5M | $45.5M | $28.2M | $25.4M |
| Gross profit | $10.5M | $11.3M | $11.4M | $9.5M | $10.6M | $11.0M | $11.4M | $12.1M | $10.4M | $24.2M | $13.4M | $11.2M |
| Gross margin | 52.4% | 53.5% | 47.8% | 48.5% | 48.8% | 54.6% | 45.8% | 54.9% | 46.1% | 53.1% | 47.4% | 44.0% |
| Operating income | -$25.4M | -$12.5M | -$24.6M | -$32.9M | -$25.7M | -$27.0M | -$26.1M | -$26.7M | -$30.3M | -$60.2M | -$21.4M | -$21.2M |
| Net income | -$26.8M | $127.1M | $19.3M | -$34.7M | -$33.5M | -$26.0M | -$34.1M | -$26.9M | -$45.7M | -$78.2M | -$19.8M | -$21.0M |
| Net margin | −133.1% | 600.9% | 81.0% | −177.4% | −153.7% | −128.7% | −137.5% | −122.0% | −203.3% | −171.7% | −70.2% | −82.8% |
| Diluted EPS | $-0.07 | $0.33 | $0.05 | $-0.09 | $-0.09 | $-0.07 | $-0.09 | $-0.07 | $-0.12 | $-0.27 | $-0.25 | $-0.27 |
| EBITDA | -$6.6M | -$8.0M | -$20.6M | -$21.9M | -$19.7M | -$20.0M | -$19.0M | -$15.4M | -$17.9M | -$33.5M | -$21.4M | -$13.5M |
| Operating cash flow | -$10.3M | -$46.6M | -$1.2M | -$22.2M | -$20.7M | -$30.3M | -$14.1M | -$27.9M | -$39.0M | -$62.5M | -$14.1M | -$11.4M |
| Free cash flow | -$10.7M | -$47.2M | -$1.7M | -$23.1M | -$22.6M | -$35.3M | -$17.4M | -$30.1M | -$41.0M | -$63.3M | -$14.1M | -$12.3M |
| Diluted shares | 390.9M | 388.2M | 385.1M | 382.6M | 380.5M | 378.2M | 375.0M | 371.5M | 372.3M | 294.1M | 79.7M | 79.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $270.0M | $265.8M | $120.9M | $129.4M | $158.6M | $150.9M |
| Short-term investments | $206.7M | $189.4M | $66.7M | $65.5M | $78.5M | $107.2M |
| Total debt | $299.0K | $299.0K | $299.0K | $299.0K | $299.0K | $299.0K |
| Total assets | $627.2M | $639.1M | $567.8M | $539.6M | $557.0M | $579.6M |
| Total liabilities | $87.2M | $78.0M | $143.5M | $140.0M | $132.4M | $125.0M |
| Shareholders' equity | $540.0M | $561.1M | $424.3M | $399.7M | $424.5M | $454.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology